Results 161 to 170 of about 31,394 (214)
Some of the next articles are maybe not open access.
Lancet. Infectious Diseases (Print), 2023
BACKGROUND Shorter treatments are needed for drug-susceptible tuberculosis. Adjunctive statins increase bactericidal activity in preclinical tuberculosis models.
G. Cross +16 more
semanticscholar +1 more source
BACKGROUND Shorter treatments are needed for drug-susceptible tuberculosis. Adjunctive statins increase bactericidal activity in preclinical tuberculosis models.
G. Cross +16 more
semanticscholar +1 more source
Drugs, 2002
Rosuvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin is not extensively metabolised and has a low propensity for drug interactions. In well designed trials of between 6 and 52 weeks' duration, rosuvastatin was superior to atorvastatin, simvastatin and ...
Christopher I, Carswell +2 more
openaire +3 more sources
Rosuvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin is not extensively metabolised and has a low propensity for drug interactions. In well designed trials of between 6 and 52 weeks' duration, rosuvastatin was superior to atorvastatin, simvastatin and ...
Christopher I, Carswell +2 more
openaire +3 more sources
The American Journal of Cardiology, 2004
The safety and tolerability of rosuvastatin were assessed (as of August 2003) using data from 12,400 patients who received 5 to 40 mg of rosuvastatin in a multinational phase II/III program, which represented 12,212 patient-years of continuous exposure to rosuvastatin. An integrated database was used to examine adverse events and laboratory data.
Shepherd, James +6 more
openaire +2 more sources
The safety and tolerability of rosuvastatin were assessed (as of August 2003) using data from 12,400 patients who received 5 to 40 mg of rosuvastatin in a multinational phase II/III program, which represented 12,212 patient-years of continuous exposure to rosuvastatin. An integrated database was used to examine adverse events and laboratory data.
Shepherd, James +6 more
openaire +2 more sources
Canadian Journal of Physiology and Pharmacology, 2021
The aim of the current study was to evaluate whether rosuvastatin was effective in attenuating cardiac injury in lipopolysaccharide(LPS)-challenged mice and H9C2 cells and identify the underlying mechanisms, focusing on the NLRP3/TLR4 pathway.
Guocheng Ren +3 more
semanticscholar +1 more source
The aim of the current study was to evaluate whether rosuvastatin was effective in attenuating cardiac injury in lipopolysaccharide(LPS)-challenged mice and H9C2 cells and identify the underlying mechanisms, focusing on the NLRP3/TLR4 pathway.
Guocheng Ren +3 more
semanticscholar +1 more source
Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia
Expert Review of Cardiovascular Therapy, 2021Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)–related morbidity and mortality. However, a large proportion of patients cannot attain the target low-density lipoprotein cholesterol (LDL-C) levels, despite ...
C. Boutari, A. Karagiannis, V. Athyros
semanticscholar +1 more source
Life Science, 2021
AIMS Vitamin D and rosuvastatin are well-known drugs that mediate beneficial effects in treating type-2 diabetes (T2D) complications; however, their anti-neuropathic potential is debatable.
Engie S El-Sawaf +4 more
semanticscholar +1 more source
AIMS Vitamin D and rosuvastatin are well-known drugs that mediate beneficial effects in treating type-2 diabetes (T2D) complications; however, their anti-neuropathic potential is debatable.
Engie S El-Sawaf +4 more
semanticscholar +1 more source
Expert Review of Clinical Pharmacology, 2021
Introduction: Reducing low-density lipoprotein cholesterol (LDL-C) with lipid-lowering therapies has been associated with a decrease in the frequency of cardiovascular events.
V. Barrios, C. Escobar
semanticscholar +1 more source
Introduction: Reducing low-density lipoprotein cholesterol (LDL-C) with lipid-lowering therapies has been associated with a decrease in the frequency of cardiovascular events.
V. Barrios, C. Escobar
semanticscholar +1 more source
Rosuvastatin enhanced functional recovery after sciatic nerve injury in the rat.
European Journal of Pharmacology, 2020Posttraumatic nerve recovery remains a challenge in regenerative medicine. As such, there is a need for agents that limit nerve damage and enhance nerve regeneration.
A. Abdolmaleki, S. Zahri, A. Bayrami
semanticscholar +1 more source
International journal of pharmaceutics, 2020
Rosuvastatin is a hypolipidemic drug of limited oral bioavailability. The aim was to develop rosuvastatin flexible chitosomes and loading into a pullulan-based tablet to improve the bioavailability and maximize the antihyperlipidemic and antioxidant ...
Tarek A. Ahmed +6 more
semanticscholar +1 more source
Rosuvastatin is a hypolipidemic drug of limited oral bioavailability. The aim was to develop rosuvastatin flexible chitosomes and loading into a pullulan-based tablet to improve the bioavailability and maximize the antihyperlipidemic and antioxidant ...
Tarek A. Ahmed +6 more
semanticscholar +1 more source